AxoGen, Inc. (NASDAQ:AXGN - Get Free Report)'s stock price dropped 6.1% during mid-day trading on Tuesday . The stock traded as low as $17.84 and last traded at $18.12. Approximately 391,834 shares traded hands during trading, a decline of 28% from the average daily volume of 541,548 shares. The stock had previously closed at $19.29.
Wall Street Analyst Weigh In
AXGN has been the subject of several recent analyst reports. Cantor Fitzgerald restated an "overweight" rating and set a $24.00 target price on shares of AxoGen in a research report on Wednesday. Canaccord Genuity Group boosted their price target on AxoGen from $22.00 to $26.00 and gave the company a "buy" rating in a report on Wednesday, February 26th. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has an average rating of "Buy" and a consensus target price of $20.75.
Check Out Our Latest Analysis on AxoGen
AxoGen Stock Down 0.2 %
The company has a market cap of $786.22 million, a P/E ratio of -55.41 and a beta of 1.00. The company has a quick ratio of 2.47, a current ratio of 3.74 and a debt-to-equity ratio of 0.67. The business's 50 day moving average is $17.90 and its 200 day moving average is $15.26.
Insider Buying and Selling
In related news, Director Amy Mcbride Wendell sold 5,000 shares of the business's stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $20.02, for a total value of $100,100.00. Following the completion of the transaction, the director now owns 97,899 shares of the company's stock, valued at $1,959,937.98. The trade was a 4.86 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. 7.00% of the stock is currently owned by insiders.
Hedge Funds Weigh In On AxoGen
A number of large investors have recently bought and sold shares of AXGN. Quest Partners LLC raised its stake in AxoGen by 23,066.7% in the third quarter. Quest Partners LLC now owns 2,085 shares of the medical equipment provider's stock worth $29,000 after buying an additional 2,076 shares in the last quarter. R Squared Ltd bought a new position in AxoGen in the fourth quarter worth approximately $30,000. US Bancorp DE acquired a new position in shares of AxoGen during the fourth quarter worth $30,000. State of Wyoming acquired a new position in shares of AxoGen during the fourth quarter worth $31,000. Finally, Harvest Fund Management Co. Ltd acquired a new position in shares of AxoGen during the fourth quarter worth $93,000. Institutional investors own 80.29% of the company's stock.
AxoGen Company Profile
(
Get Free Report)
AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.
Featured Stories
Before you consider AxoGen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AxoGen wasn't on the list.
While AxoGen currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.